142 related articles for article (PubMed ID: 33946955)
1. Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations.
Wu CE; Ng CT; Tan KT
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946955
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
3. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.
Glade Bender JL; Pinkney K; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
Oncologist; 2024 May; ():. PubMed ID: 38815151
[TBL] [Abstract][Full Text] [Related]
4. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Gomez MK; Illuzzi G; Colomer C; Churchman M; Hollis RL; O'Connor MJ; Gourley C; Leo E; Melton DW
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526907
[TBL] [Abstract][Full Text] [Related]
5. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
[TBL] [Abstract][Full Text] [Related]
7. Primary pulmonary artery sarcoma: A rare and overlooked differential diagnosis of pulmonary embolism. Clues to diagnosis.
Al-Mehisen R; Al-Halees Z; Alnemri K; Al-Hemayed W; Al-Mohaissen M
Int J Surg Case Rep; 2019; 65():15-19. PubMed ID: 31675686
[TBL] [Abstract][Full Text] [Related]
8. Primary pulmonary artery sarcoma: a close associate of pulmonary embolism-20-year observational analysis.
Bandyopadhyay D; Panchabhai TS; Bajaj NS; Patil PD; Bunte MC
J Thorac Dis; 2016 Sep; 8(9):2592-2601. PubMed ID: 27747013
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With
Wang W; Zhang X; Fang Y; He J; Huang J; Li S; Ma T; Li L
Front Oncol; 2022; 12():808801. PubMed ID: 35480123
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
13. Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase.
Campillo-Marcos I; Lazo PA
J Exp Clin Cancer Res; 2019 May; 38(1):203. PubMed ID: 31101118
[TBL] [Abstract][Full Text] [Related]
14. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
[TBL] [Abstract][Full Text] [Related]
15. Response to olaparib in a
Horak P; Weischenfeldt J; von Amsberg G; Beyer B; Schütte A; Uhrig S; Gieldon L; Klink B; Feuerbach L; Hübschmann D; Kreutzfeldt S; Heining C; Maier S; Hutter B; Penzel R; Schlesner M; Eils R; Sauter G; Stenzinger A; Brors B; Schröck E; Glimm H; Fröhling S; Schlomm T
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833416
[TBL] [Abstract][Full Text] [Related]
16. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
17. Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors.
Yang Z; Cui W; Yu R; Dong X; Zhao J; Dai L; Ou Q; Bao H; Wu X; Wu C; Lai J
Front Oncol; 2022; 12():753311. PubMed ID: 35402276
[TBL] [Abstract][Full Text] [Related]
18. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
20. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
